KROS Keros Therapeutics, Inc.
Healthcare$11.19-0.27%ClosedMarket Cap: $358.1M
As of 2026-05-25
Valuation
P/E (TTM)
4.79
PEG
0.03
P/B
1.46
P/S
10.79
EV/EBITDA
-0.98
DCF Value
$-58.69
FCF Yield
-16.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.5%
Operating Margin
-332.6%
Net Margin
-256.6%
ROE
-17.0%
ROA
-27.3%
ROIC
-34.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $367.0K | -9.8% | $-25.9M | $-23.7M | $— | — |
| Q4 null | $385.0K | 100.0% | $-29.3M | $-23.5M | $— | — |
| FY null | $244.1M | 99.4% | $70.6M | $87.0M | $— | — |
| Q3 null | $14.3M | 97.2% | $-15.4M | $-7.3M | $— | — |
| Q2 null | $18.2M | 98.0% | $-39.8M | $-30.7M | $— | — |
| Q1 null | $211.2M | 100.0% | $152.0M | $148.5M | $— | — |
| Q4 null | $3.0M | 89.1% | $-53.3M | $-46.0M | $— | — |
| FY null | $3.5M | 100.0% | $-210.8M | $-187.4M | $— | — |
| Q3 null | $388.0K | 19.1% | $-58.7M | $-53.0M | $— | — |
| Q2 null | $37.0K | 100.0% | $-50.4M | $-45.3M | $— | — |
| Q1 null | $83.0K | 100.0% | $-48.5M | $-43.1M | $— | — |
| Q4 2023 | $143.0K | 100.0% | $-46.5M | $-40.2M | $-1.34 | — |